Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
SAN FRANCISCO, CA, August 5, 2008 — Gilead Sciences and Merck & Co., Inc. have entered into an agreement through which Gilead will assume the lead role for the distribution of the HIV medication Atripla(R) in 12 countries located primarily in Latin America and the Asia-Pacific region. Covington & Burling LLP advised Gilead in the agreement.
Atripla is the first once-daily single table regimen for HIV. Under the terms of the agreement, Gilead will assume the lead role in the registration, manufacturing and distribution of Altripla in Argentina, Australia, Chile, Hong Kong, Israel, Mexico, New Zealand, Russia, Taiwan, Thailand, Turkey and Uruguay.
The Covington corporate team was led by partners James Snipes and Emily Leonard, and associates Amy Toro, Emily Mason, and Chelsea Tanaka-Delgado. All are resident in the firm’s San Francisco office except for Ms. Leonard, who is resident in the Washington office.